What is the current stock price of BioNTech SE (BNTX)?

As of the latest market data, BioNTech SE (BNTX) is trading at $95.50. The stock has seen a gain of 3.83% today.

Does BioNTech SE (BNTX) pay a dividend?

Based on current data, BioNTech SE does not have a confirmed active dividend policy.

What is the market cap of BioNTech SE?

The current market capitalization of BioNTech SE (BNTX) is approximately unavailable.

BNTX

BioNTech SE·Healthcare

95.50

3.827%(+3.52)

Market Closed

98.14

2.764%(+2.64)

After Hours

Last Updated: — ET

52W L: $79.5252W H: $124.00

BNTX NEWS

reuters.com

Apr 1

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Vaccine makers Pfizer ‌and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.

247wallst.com

Mar 30

3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.

globenewswire.com

Mar 24

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate (“ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech's clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.

barrons.com

Mar 17

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

The first severe case of the virus has been detected in New York.

feeds.benzinga.com

Mar 11

BioNTech Analysts Slash Their Forecasts After Q4 Earnings

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

fool.com

Mar 10

Stock Market Today, March 10: Oil Prices Drop on G7 Talks

On March 10, 2026, Oracle outperformed in after-hours trading and oil prices fell in a volatile, energy-driven session.

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Sector

Healthcare

Industry

Biotechnology

Employees

6,772

IPO Date

2019-10-10

Beta

1.59

Websitewww.biontech.de↗